3D Printed Cancer Models for Pre-clinical Research

目前开发新的抗癌治疗方法的研究受到缺乏合适的临床前模型进行测试的限制。目前，癌症研究依赖于动物模型和基本细胞模型，这两种模型都不能很好地代表人类癌症。这些模型不能有效复制已知在耐药性中起关键作用的肿瘤微环境，因此这些模型不能准确反映这些药物在体内如何相互作用，也不能准确反映它们在治疗癌症方面的疗效。Carcinotech的3D生物打印模型旨在解决这些缺点，包括从人类癌症活检样本中分离出来的患者细胞、免疫细胞和癌症干细胞。因此，Carcinotech的模型准确地反映了肿瘤结构和癌症微环境，从而产生了一个更有效和更具说明性的模型，可用于药物测试和药物发现、临床前测试，以及作为个性化的药物分析工具。在已经开发了商业胶质母细胞瘤3D打印模型之后，我们计划利用这笔赠款来合成和验证卵巢癌、肺癌和乳腺癌的类似模型。

Current research into developing new anti-cancer treatments is constrained by a lack of suitable pre-clinical models to test them in. At present, cancer research is reliant on animal models and basic cellular models, neither of which are a good representation of human cancers. These models do not effectively replicate the tumour microenvironment that is known to play a critical role in drug resistance, thereby these models do not accurately reflect how these drugs will interact in the body, nor their efficacy in treating the cancer. Carcinotech's 3D bioprinted models aim to address these shortcomings, incorporating patient cells, immune cells, and cancer stem cells that are isolated from human cancer biopsy samples. As such, Carcinotech's models accurately reflect the tumour structure and the cancer microenvironment, resulting in a more valid and illustrative model that can be used for drug testing and drug discovery, for pre-clinical testing, and as a personalised medicine analysis tool. Having already developed commercial glioblastoma 3D printed models, we plan to use this grant to synthesise and validate similar models for ovarian, lung, and breast cancer.